BrightPath Biotherapeutics Co., Ltd. announced a private placement to issue 156,600 16th stock acquisition rights at an issue price of ¥33 per right for the gross proceeds of ¥5,167,800 and 2nd unsecured bonds for the gross proceeds of ¥5,167,800 on November 14, 2023. The transaction will include participation from new investor Macquarie Group Limited. The transaction has been approved by the shareholders of the company and is expected to close on November 30, 2023.

The exercise price of rights is from December 1, 2023 to November 30, 2026. The initial exercise price of rights is ¥104. The company has disclosed the issue expenses of ¥20,000,000.